Last reviewed · How we verify
Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fragmin | Dalteparin Sodium | Pfizer Inc. | Low molecular weight heparin (LMWH) | Factor Xa and thrombin |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery:
- Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery treatment updates — RSS
- Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery treatment updates — Atom
- Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prophylaxis-of-deep-vein-thrombosis-in-patients-undergoing-abdominal-surgery. Accessed 2026-06-10.
Related
- Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing